Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids. (2nd November 2019)

• Record Type: Journal Article
• Authors: Shih, Vanessa; Banks, Erika; Bonine, Nicole G.; Harrington, Amanda; Stafkey-Mailey, Dana; Yue, Binglin; Ye, Jiatao Michael; Fuldeore, Rupali M.; Gillard, Patrick
• Is Part Of: Current medical research and opinion. Volume 35:Number 11(2019)
• Page Start: 1925
• Page End: 1935
• Publication Date: 2019-11-02
• Subjects: Cost -- economic burden -- healthcare resource utilization -- leiomyomata -- uterine fibroids; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2019.1642186
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205, 098 (Commercial) and 24, 755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher ( p < .0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14, 917 for cases versus $5717 for controls in the Commercial population, and $20, 244 versus $10, 544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p < .05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.